Combining anti-PD-1 therapy with nano-drug composed of an Monocarboxylate transporter 1 (MCT1) inhibitor loaded inside the ultra-pH-sensitive nanoparticles increases the effect of T cells and decreases exhaustion of T cells, significantly reducing tumor volume and prolonging survival (72). Here, SLC16A1 is linked to neoplasm.